Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00934375 · ClinicalTrials.gov registry record · Phase 4
A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment
A Phase 4 study of Mild Cognitive Impairment, sponsored by Eisai.
- Completed
- Registry status
- Phase 4
- Development phase
- 145
- Enrollment target
- 20
- Study locations
NCT00934375 is a Phase 4 study of Mild Cognitive Impairment that has completed, run by Eisai. The registered enrollment target is 145 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00934375, a Phase 4 study of Mild Cognitive Impairment, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 145 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, open-label study of 28 weeks duration in subjects with Mild Cognitive Impairment who have completed the double-blind study (E2020-A001-412).
Conditions Studied
Interventions
- DRUG placebo
- DRUG Aricept (donepezil hydrochloride)
Study Locations (20)
California
- The Neurology Center - Encinitas
- Margolin Brain Institute - Fresno
- Colaborative Neuroscience Network (CNS Network) - Garden Grove
- Nerve Pro Research - Irvine
- Optimum Health Services - La Mesa
- Pacific Research Network - San Diego
- Neurological Research Institute - Santa Monica
- CA Neuroscience Research - Sherman Oaks
- Pacific Research Network - Vista
Florida
- North Broward Medical Center Memory Disorder Center - Deerfield Beach
- Neurologic Consultants - Fort Lauderdale
- Berma Research Group - Hialeah
- Sunrise Clinical Research - Hollywood
- Wien Center for Memory Disorders, Mount Sinai Medical Center - Miami Beach
- Berma Research Group - Plantation
Arizona
- Pivotal Research Centers - Peoria
- Sun Health Research Institute - Sun City
- Northwest Neurospecialists, PLLC - Tucson
Alabama
- Neurology Neurodiagnostic Lab, LLC - Alabaster
Connecticut
- Yale University Alzheimers Disease Research Unit School of Medicine Department of Psychiatry - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00934375
The ClinicalTrials.gov registry entry for NCT00934375 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (89% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00934375 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00934375 about?
NCT00934375 is a clinical study titled "A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment". This is a multi-center, open-label study of 28 weeks duration in subjects with Mild Cognitive Impairment who have completed the double-blind study (E2020-A001-412).
What is the current status of trial NCT00934375?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 145 participants. The study started on 2006-02. Estimated completion is 2007-09.
What conditions does trial NCT00934375 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
What interventions are being tested in trial NCT00934375?
The interventions under investigation include: placebo (DRUG), Aricept (donepezil hydrochloride) (DRUG).
Who is sponsoring clinical trial NCT00934375?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00934375 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Water-based Activity to Enhance Recall in Veterans
ACTIVE NOT RECRUITING · Phase 4
-
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
COMPLETED · Phase 4
-
Combination Treatment Study for Memory Impairment and Depression
COMPLETED · Phase 4
-
Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia
COMPLETED · Phase 4
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.